Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. The Food and Drug Administration has approved revised ...
Ironwood and AbbVie can now add “bloating” and “discomfort” to marketing for irritable bowel syndrome with constipation (IBS-C) drug Linzess, thanks to a supplemental NDA approval from the FDA Sept.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...
Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results